Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Design Principles
EU AI Act Spurs AI Grid Forecasting for German Energy Networks
Four TSOs jointly trial data-driven forecasts across real-time, intraday, and day-ahead timescales. Meanwhile, the EU AI Act declares such models high-risk for critical infrastructure tasks. Developers must now balance speed, accuracy, and regulatory compliance throughout product lifecycles. Subsequently, industry consortia such as AI.Grids coordinate open technology roadmaps across 48 partners. Global analysts value AI in power utilities at roughly USD 17.3 billion for 2025.
Pippigate Exposes AI Ethics Failures in Adobe Classroom Tools
State officials soon revised guidance, signaling a broader reckoning around classroom generative AI use. At the center stands AI Ethics, a lens now framing every decision about algorithmic creativity in schools. Meanwhile, similar incidents nationwide revealed systemic gaps, from deepfake bullying to surging child-safety hotline reports. This article unpacks the data, reactions, and emerging solutions shaping safer digital Education environments.
Prioritising VAPT Based On The OWASP Top 10
Cybersecurity is receiving a great deal of emphasis in boardrooms due to the destructive potential of cyberattacks, but the emphasis is accompanied by uncertainty – where should attention be directed? Digital infrastructure in modern organisations is very complex which is further compounded by operations that are distributed across regions, requiring compliance with multiple regulatory requirements.
Circular Design & Biomimicry Market Forecasts to 2032 - Global Analysis By Design Principles, Biomimicry Domains, Technology, Application, End User and By Geography
According to Stratistics MRC, the Global Circular Design & Biomimicry Market is accounted for $21.25 billion in 2025 and is expected to reach $60.41 billion by 2032 growing at a CAGR of 16.1% during the forecast period. Circular design and biomimicry offer a sustainable blueprint for modern innovation. Circular design focuses on eliminating waste by ensuring products are repairable, reusable, or recyclable, extending their lifecycle.
Council Post: How To Overcome Common Hurdles In Adopting DevSecOps
Taking a more proactive and culture-based approach to security, DevSecOps stresses integrating and maintaining a focus on security in operations and throughout the software development life cycle. The benefits? Security and resilience become a shared responsibility rather than an afterthought. It’s easier to maintain compliance with changing and growing regulations. And time to market for new releases and updates is often faster.
CISA Red Team’s Operations Against a Federal Civilian Executive Branch Organization Highlights the Necessity of Defense-in-Depth
2024-07-09 16:09 (CEST) US CERT EXECUTIVE SUMMARY In early 2023, the Cybersecurity and Infrastructure Security Agency (CISA) conducted a SILENTSHIELD red team assessment against a Federal Civilian Executive Branch (FCEB) organization. During SILENTSHIELD assessments, the red team first performs a no-notice, long-term simulation of nation-state cyber operations.
Council Post: 20 Tools And Strategies For Safe And Efficient AI System Data Sharing
Companies increasingly rely on artificial intelligence tools to drive decision-making and streamline operations. But to achieve the best ROI in terms of cost and efficiency benefits, secure and smooth data sharing among AI systems is critical. There are many tools and strategies organizations can leverage to smartly manage data sharing, from standardizing formats to establishing strict access controls (and more).
OpenAI's Commitment To Child Safety: Adopting Safety By Design Principles
OpenAI, alongside industry leaders including Amazon, Anthropic, Civitai, Google, Meta, Metaphysic, Microsoft, Mistral AI, and Stability AI, has committed to implementing robust child safety measures in the development, deployment, and maintenance of generative AI technologies as articulated in the Safety by Design principles.
Analyzing CISA KEV Data to Understand Danger
In our continuing series on the CISA Known Exploited Vulnerabilities (KEV) catalog, we provide an update on the landscape of cyber threats as it has evolved since March 2023. The KEV list, an essential tool for cybersecurity professionals, highlights vulnerabilities that have been actively exploited by cyber adversaries. The KEV is a small subset of total published vulnerabilities and provides the defenders with an idea of what vulnerabilities attackers are actually going after.
Threat Actors Exploit Multiple Vulnerabilities in Ivanti Connect Secure and Policy Secure Gateways
2024-02-21 21:30 (CET) US CERT SUMMARY The Cybersecurity and Infrastructure Security Agency (CISA) and the following partners (hereafter referred to as the authoring organizations) are releasing this joint Cybersecurity Advisory to warn that cyber threat actors are exploiting previously identified vulnerabilities in Ivanti Connect Secure and Ivanti Policy Secure gateways.
Align AI by design (or risk decline)
As my colleague Brian Hopkins pointed out in his blog We Are Launching Research on AI Alignment And Trust, the challenge of alignment in AI is one that we can't afford to ignore. While the sci-fi tinged existential risk to humanity may loom in the far distance, the risk to your business today is real and increasing as AI grows in power at an exponential pace. You can't afford to sit back and wait, the opportunities in AI are too big. But you can't afford to deploy misaligned systems either.
Align AI By Design (Or Risk Decline)
As my colleague Brian Hopkins pointed out in his blog We Are Launching Research on AI Alignment And Trust, the challenge of alignment in AI is one that we can’t afford to ignore. While the sci-fi tinged existential risk to humanity may loom in the far distance, the risk to your business today is real and increasing as AI grows in power at an exponential pace. You can’t afford to sit back and wait, the opportunities in AI are too big. But you can’t afford to deploy misaligned systems either.
CISA Launches Secure by Design Pledge with 6 Ed Tech Vendors
Security and Data Privacy The Cybersecurity and Infrastructure Security Agency has launched a voluntary pledge for K–12 education technology software makers to “commit to designing products with greater security built in,” the agency said in a news release. The new program was unveiled with commitments already in place from six of the industry’s most-recognized names, including PowerSchool, Classlink, Clever, GG4L, Instructure, and D2L.
09.01.23 -- Designing Patient-Centric Dosage Forms
Developers continue to realize the strong therapeutic potential of HPAPIs, particularly in areas such as oncology.
09.01.23 -- Designing Patient-Centric Dosage Forms
Get more pharma outsourcing insight with our FREE newsletter Newsletter | September 1, 2023 Developers continue to realize the strong therapeutic potential of HPAPIs, particularly in areas such as oncology.
09.01.23 -- Designing Patient-Centric Dosage Forms
Sign up today for your FREE subscription to Life Science Leader Magazine! Newsletter | September 1, 2023 Developers continue to realize the strong therapeutic potential of HPAPIs, particularly in areas such as oncology.
04.27.23 -- Leveraging Quality By Design Principles To Advance Analytical Methods
Get more pharma manufacturing insight with our FREE newsletter sign me up Newsletter | April 27, 2023 A formulation demonstrates higher patient preference and adherence to prescriptions compared to traditional tablets for Selegiline in Parkinson’s disease and other therapeutic areas. Discover how innovative modified release technologies and formulation, production scale-up, regulatory, and commercial expertise can optimize your therapeutic profile.
04.27.23 -- Leveraging Quality By Design Principles To Advance Analytical Methods
Get more pharma outsourcing insight with our FREE newsletter sign me up Development Contract Manufacturing Packaging Logistics Market Research Newsletter | April 27, 2023 A formulation demonstrates higher patient preference and adherence to prescriptions compared to traditional tablets for Selegiline in Parkinson’s disease and other therapeutic areas.
04.27.23 -- Leveraging Quality By Design Principles To Advance Analytical Methods
Sign up today for your FREE subscription to Life Science Leader Magazine! sign me up Newsletter | April 27, 2023 A formulation demonstrates higher patient preference and adherence to prescriptions compared to traditional tablets for Selegiline in Parkinson’s disease and other therapeutic areas. Discover how innovative modified release technologies and formulation, production scale-up, regulatory, and commercial expertise can optimize your therapeutic profile.
04.27.23 -- Leveraging Quality By Design Principles To Advance Analytical Methods
Get more pharma outsourcing insight with our FREE newsletter sign me up Development Contract Manufacturing Packaging Logistics Market Research Newsletter | April 27, 2023 A formulation demonstrates higher patient preference and adherence to prescriptions compared to traditional tablets for Selegiline in Parkinson’s disease and other therapeutic areas.
04.26.23 -- Leveraging Quality By Design Principles To Advance Analytical Methods
Get more pharma manufacturing insight with our FREE newsletter sign me up Newsletter | April 26, 2023 A formulation demonstrates higher patient preference and adherence to prescriptions compared to traditional tablets for Selegiline in Parkinson’s disease and other therapeutic areas. Discover how innovative modified release technologies and formulation, production scale-up, regulatory, and commercial expertise can optimize your therapeutic profile.
04.25.23 -- Driving Down The Cost Of Goods For Viral Gene Therapies
Gene therapies for ultra-rare diseases will be commercially viable only if we drive costs down. There is a need for real innovation to help shift the paradigm of the cost per dose. In this article, Emmanuelle Cameau, strategic technology partnership leader, cell and gene therapy, Pall Corporation, discusses how a combination of optimizing your process development, and process intensification can help drive down the cost of doses.
04.25.23 -- Driving Down The Cost Of Goods For Viral Gene Therapies
Get more biosimilar development insight with our FREE newsletter sign me up Home Development Manufacturing Regulatory Editorial Board Newsletter | April 25, 2023 Interested in strategies to streamline your viral vector process development and manufacturing scale up while reducing risk and costs? We invite you to utilize these technical resources. Gene therapies for ultra-rare diseases will be commercially viable only if we drive costs down.
04.24.23 -- Driving Down The Cost Of Goods For Viral Gene Therapies
Get more pharma outsourcing insight with our FREE newsletter sign me up Development Contract Manufacturing Packaging Logistics Market Research Newsletter | April 24, 2023 Interested in strategies to streamline your viral vector process development and manufacturing scale up while reducing risk and costs? We invite you to utilize these technical resources. Gene therapies for ultra-rare diseases will be commercially viable only if we drive costs down.
04.24.23 -- Driving Down The Cost Of Goods For Viral Gene Therapies
Sign up today for your FREE subscription to Life Science Leader Magazine! sign me up Newsletter | April 24, 2023 Interested in strategies to streamline your viral vector process development and manufacturing scale up while reducing risk and costs? We invite you to utilize these technical resources. Gene therapies for ultra-rare diseases will be commercially viable only if we drive costs down. There is a need for real innovation to help shift the paradigm of the cost per dose.
04.19.23 -- Driving Down The Cost Of Goods For Viral Gene Therapies
Get more Cell & Gene insight with our FREE newsletter sign me up Discovery Trials Regulatory Outsourcing Commercialization Newsletter | April 19, 2023 Interested in strategies to streamline your viral vector process development and manufacturing scale up while reducing risk and costs? We invite you to utilize these technical resources. Gene therapies for ultra-rare diseases will be commercially viable only if we drive costs down.
04.18.23 -- Driving Down The Cost Of Goods For Viral Gene Therapies
Get more pharma manufacturing insight with our FREE newsletter sign me up Newsletter | April 18, 2023 Interested in strategies to streamline your viral vector process development and manufacturing scale up while reducing risk and costs? We invite you to utilize these technical resources. Gene therapies for ultra-rare diseases will be commercially viable only if we drive costs down. There is a need for real innovation to help shift the paradigm of the cost per dose.
04.17.23 -- Driving Down The Cost Of Goods For Viral Gene Therapies
Get more Bioprocess insight with our FREE newsletter sign me up Newsletter | April 17, 2023 Interested in strategies to streamline your viral vector process development and manufacturing scale up while reducing risk and costs? We invite you to utilize these technical resources. Gene therapies for ultra-rare diseases will be commercially viable only if we drive costs down. There is a need for real innovation to help shift the paradigm of the cost per dose.
01.10.23 -- Micronization Technology For HPAPI Development & Manufacturing
Sign up today for your FREE subscription to Life Science Leader Magazine! sign me up Newsletter | January 10, 2023 Explore how to classify HPAPIs in early development and recommendations for safe product handling, from clinical manufacturing to commercialization, as well as key advantages of using micronization technology for the development and manufacture of HPAPIs. A QbD approach was used to solve a high-performance liquid chromatography analytical method problem where impurity peaks had...
01.10.23 -- Micronization Technology For HPAPI Development & Manufacturing
Get more pharma manufacturing insight with our FREE newsletter sign me up Newsletter | January 10, 2023 Explore how to classify HPAPIs in early development and recommendations for safe product handling, from clinical manufacturing to commercialization, as well as key advantages of using micronization technology for the development and manufacture of HPAPIs. A QbD approach was used to solve a high-performance liquid chromatography analytical method problem where impurity peaks had shifting...
01.10.23 -- Micronization Technology For HPAPI Development & Manufacturing
Get more pharma outsourcing insight with our FREE newsletter sign me up Development Contract Manufacturing Packaging Logistics Market Research Newsletter | January 10, 2023 Explore how to classify HPAPIs in early development and recommendations for safe product handling, from clinical manufacturing to commercialization, as well as key advantages of using micronization technology for the development and manufacture of HPAPIs. A QbD approach was used to solve a high-performance liquid...
10.24.22 -- Mitigating Common Pitfalls In Early Drug Development
Sign up today for your FREE subscription to Life Science Leader Magazine! sign me up Newsletter | October 24, 2022 This report includes expert guidance on navigating development and manufacturing challenges with orphan drugs, with insights on how drug sponsors of all sizes work with CDMOs to achieve their goals. The absence of available pediatric dosage forms can lead to increased potential for dosing errors or nonadherence.
10.23.22 -- Mitigating Common Pitfalls In Early Drug Development
Get more pharma manufacturing insight with our FREE newsletter sign me up Newsletter | October 23, 2022 This report includes expert guidance on navigating development and manufacturing challenges with orphan drugs, with insights on how drug sponsors of all sizes work with CDMOs to achieve their goals. The absence of available pediatric dosage forms can lead to increased potential for dosing errors or nonadherence.
09.14.22 -- Integrated Solutions Facilitate AAV Manufacturing
Get more pharma manufacturing insight with our FREE newsletter sign me up Newsletter | September 14, 2022 Interested in strategies to streamline your adeno-associated virus (AAV) process development and manufacturing? We invite you to utilize these technical resources and discover how a scalable, end-to-end integrated solutions approach enables viral vector manufacturing, and reduces time to market.
09.13.22 -- Integrated Solutions Facilitate AAV Manufacturing
Get more BioProcess insight with our FREE newsletter sign me up Newsletter | September 13, 2022 Interested in strategies to streamline your adeno-associated virus (AAV) process development and manufacturing? We invite you to utilize these technical resources and discover how a scalable, end-to-end integrated solutions approach enables viral vector manufacturing, and reduces time to market.
06.02.22 -- Oral Delivery: Analytical Methods, Formulation, & Early Development
Sign up today for your FREE subscription to Life Science Leader Magazine! sign me up Newsletter | June 2, 2022 A QbD approach was used to solve a high-performance liquid chromatography analytical method problem where impurity peaks had shifting retention times, making identification and quantitation problematic. Salmon Calcitonin is a peptide with poor oral bioavailability.
06.02.22 -- Oral Delivery: Analytical Methods, Formulation, & Early Development
Get more pharma manufacturing insight with our FREE newsletter sign me up Newsletter | June 2, 2022 A QbD approach was used to solve a high-performance liquid chromatography analytical method problem where impurity peaks had shifting retention times, making identification and quantitation problematic. Salmon Calcitonin is a peptide with poor oral bioavailability.
02.10.22 -- Advanced Analytical Tools For Drug Product Development
Raman spectroscopy is used to compare the dissolution rates and pellet fine structure of branded Sporanox® with three similar generic products marketed across the world, all containing the same API. This Q&A with two formulation and bioavailability experts addresses some common formulation challenges for pediatric populations.
02.07.22 -- Advanced Analytical Tools For Drug Product Development
Raman spectroscopy is used to compare the dissolution rates and pellet fine structure of branded Sporanox® with three similar generic products marketed across the world, all containing the same API. This Q&A with two formulation and bioavailability experts addresses some common formulation challenges for pediatric populations.
12.10.21 -- Oral Delivery: Unique Technologies And Techniques
Discover how Raman spectroscopy is used to analyze a chemical compound’s structure and an example of how this technique is used to analyze amorphous material created through a hot melt extrusion process. A unique technology enables administration by sublingual dose and offers several benefits that differentiate it from other orally disintegrating tablet technologies on the market.
12.08.21 -- Oral Delivery: Unique Technologies And Techniques
Discover how Raman spectroscopy is used to analyze a chemical compound’s structure and an example of how this technique is used to analyze amorphous material created through a hot melt extrusion process. A unique technology enables administration by sublingual dose and offers several benefits that differentiate it from other orally disintegrating tablet technologies on the market.
12.07.21 -- Oral Delivery: Unique Technologies And Techniques
Discover how Raman spectroscopy is used to analyze a chemical compound’s structure and an example of how this technique is used to analyze amorphous material created through a hot melt extrusion process. A unique technology enables administration by sublingual dose and offers several benefits that differentiate it from other orally disintegrating tablet technologies on the market.
04.23.21 -- Improved Bioavailability In 12 Weeks
An orally disintegrating tablet (ODT) is designed to rapidly dissolve on contact with saliva. This webinar presents the Zydis® ODT technology, a unique freeze-dried tablet, and introduces Zydis Ultra, which incorporates coated APIs for enhanced taste masking at a higher dose strength.
10 key mobile UX design principles
8 minutes read A mobile phone is a very different beast to a desktop or laptop computer. Sure they all talk the same binary language of 1s and 0s, but how we interact with them, when, where and how we use them, even our relationship with them is very different. Designing for mobile requires a slightly different mind-set to designing for desktop. It requires a slightly different skillset, and it certainly requires a different rule book.
The Art of Gene Therapy Digital Summit
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The Art of Gene Therapy Digital Summit
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
11 Ways To Address Security From The Start Of Your Tech Project
Tech leaders are generally in agreement that their aim should be to build security into their products from the ground up. However, this requires detailed planning before execution. Today's globally connected tech environment has made cybersecurity a bigger necessity than ever before. Without adequately developed security frameworks, products and entire companies may be left vulnerable to malicious attacks.
Secure In-Memory Computing Security Bulletin
Stay updated with the latest security bulletins for Secure In-Memory Computing Solutions, ensuring your data remains protected. The framework for autonomous intelligence The development of a machine-learning accelerator by researchers at MIT and the MIT-IBM Watson AI Lab addresses critical security vulnerabilities associated with edge devices.
Secure In-Memory Computing Solutions Architecture
Explore secure AI system architecture design principles for robust in-memory computing solutions. The framework for autonomous intelligence Artificial intelligence (AI) is revolutionizing various sectors, but it also introduces significant security challenges. To design secure AI system architectures, it is crucial to focus on three core tenets: secure code, secure data, and secure access.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Design
Contact Design, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack